Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity

Nature

Volumn 525, Issue 7567, 2015, Pages 119-123

  Van Keymeulen, Alexandra ^a   Lee, May Yin ^a   Ousset, Marielle ^a   Brohée, Sylvain ^b   Rorive, Sandrine ^c,d   Giraddi, Rajshekhar R ^a   Wuidart, Aline ^a   Bouvencourt, Gaëlle ^a   Dubois, Christine ^a   Salmon, Isabelle ^c,d   Sotiriou, Christos ^b   Phillips, Wayne A ^e,f   Blanpain, Cédric ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d DIAPATH   (Belgium)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LONG UNTRANSLATED RNA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR RUNX2; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PIK3CA PROTEIN, MOUSE;

CANCER; CELLS AND CELL COMPONENTS; ESTROGENIC COMPOUND; GENE EXPRESSION; GENETIC ANALYSIS; HETEROGENEITY; MOLECULAR ANALYSIS; MUTATION; PROTEIN; RODENT; TUMOR; WOMENS HEALTH;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BASAL CELL; BASAL LIKE BREAST CANCER; BREAST CANCER; CELL DIFFERENTIATION; CELL FATE; CELL HETEROGENEITY; CELL LINEAGE; CONTROLLED STUDY; ENZYME REACTIVATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUMINAL B BREAST CANCER; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; BREAST TUMOR; CELL DIVISION; CELL TRANSFORMATION; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHENOTYPE; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

MUS;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, P53; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MUTATION; NEOPLASM INVASIVENESS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84940919933     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14665     Document Type: Article

References (43)

1. Weigelt, B., Geyer, F. C. & Reis-Filho, J. S. Histological types of breast cancer: how special are they? Mol. Oncol. 4, 192-208 (2010).
2. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
3. Network, C. G. A. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
4. H1047R mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERa-positive tumors. PLoS ONE 7, e36924 (2012).
5. Prat, A., Ellis, M. J. & Perou, C. M. Practical implications of gene-expression-based assays for breast oncologists. Nature Rev. Clin. Oncol. 9, 48-57 (2012).
6. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 486, 395-399 (2012).
7. Stemke-Hale, K. et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68, 6084-6091 (2008).
8. López-Knowles, E. et al. PI3Kpathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int. J. Cancer 126, 1121-1131 (2010).
9. Tilch, E. et al. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Res. Treat. 143, 385-392 (2014).
10. Adams, J. R. et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 71, 2706-2717 (2011).
11. Liu, P. et al. Oncogenic PIK3CA-drivenmammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature Med. 17, 1116-1120 (2011).
12. H1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32, 318-326 (2013).
13. Meyer, D. S. et al. Luminal expression of PIK3CAmutant H1047R in themammary gland induces heterogeneous tumors. Cancer Res. 71, 4344-4351 (2011).
14. Van Keymeulen, A. et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature 479, 189-193 (2011).
15. Rios, A. C., Fu, N. Y., Lindeman, G. J. & Visvader, J. E. In situ identification of bipotent stem cells in the mammary gland. Nature 506, 322-327 (2014).
16. Wang, D. et al. Identification of multipotent mammary stem cells by protein C receptor expression. Nature 517, 81-84 (2015).
17. Hayes, M. M. Adenomyoepithelioma of the breast: a review stressing its propensity for malignant transformation. J. Clin. Pathol. 64, 477-484 (2011).
18. Shackleton, M. et al. Generation of a functional mammary gland froma single stem cell. Nature 439, 84-88 (2006).
19. Stingl, J. et al. Purification andunique properties of mammary epithelial stemcells. Nature 439, 993-997 (2006).
20. Shehata, M. et al. Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res. 14, R134 (2012).
21. Standaert, L. et al. The long noncoding RNA Neat1 is required for mammary gland development and lactation. RNA 20, 1844-1849 (2014).
22. Owens, T. W. et al. Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer. Cancer Res. 74, 5277-5286 (2014).
23. Jin, W. et al. TrkC plays an essential role in breast tumor growth and metastasis. Carcinogenesis 31, 1939-1947 (2010).
24. + cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model. Oncogene 34, 761-770 (2015).
25. Euhus, D. M., Timmons, C. F. & Tomlinson, G. E. ETV6-NTRK3-Trking the primary event in human secretory breast cancer. Cancer Cell 2, 347-348 (2002).
26. Li, Z. et al. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell 12, 542-558 (2007).
27. Milovanovic, M. et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 52, 89-99 (2012).
28. Wu, J. et al. Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene 31, 333-341 (2012).
29. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
30. Haibe-Kains, B. et al. A three-gene model to robustly identify breast cancer molecular subtypes. J. Natl. Cancer Inst. 104, 311-325 (2012).
31. Srinivas, S. et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4 (2001).
32. Nguyen, H., Rendl, M. & Fuchs, E. Tcf3 governs stemcell features and represses cell fate determination in skin. Cell 127, 171-183 (2006).
33. Perl, A. K., Wert, S. E., Nagy, A., Lobe, C. G. & Whitsett, J. A. Early restriction of peripheral and proximal cell lineages during formation of the lung. Proc. Natl Acad. Sci. USA 99, 10482-10487 (2002).
34. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet. 29, 418-425 (2001).
35. Shehata, M., van Amerongen, R., Zeeman, A. L., Giraddi, R. R. & Stingl, J. The influence of tamoxifen on normal mouse mammary gland homeostasis. Breast Cancer Res. 16, 411 (2014).
36. Rorive, S. et al. TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas. Mod. Pathol. 23, 1418-1428 (2010).
37. Beck, B. et al. A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478, 399-403 (2011).
38. McCall, M. N., Bolstad, B. M. & Irizarry, R. A. Frozen robust multiarray analysis (fRMA). Biostatistics 11, 242-253 (2010).
39. Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
40. Suzuki, R. & Shimodaira, H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22, 1540-1542 (2006).
41. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
42. Kasprzyk, A. BioMart: driving a paradigm change in biological data management. Database 2011, bar049 (2011).
43. Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882-883 (2012).